Connection

Giuliano Rizzardini to Aged

This is a "connection" page, showing publications Giuliano Rizzardini has written about Aged.
Connection Strength

0.067
  1. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018 12; 19(6):242-248.
    View in: PubMed
    Score: 0.014
  2. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. Eur J Gastroenterol Hepatol. 2018 10; 30(10):1208-1215.
    View in: PubMed
    Score: 0.014
  3. Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy. Intern Emerg Med. 2021 08; 16(5):1173-1181.
    View in: PubMed
    Score: 0.004
  4. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
    View in: PubMed
    Score: 0.004
  5. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020 08; 158:104931.
    View in: PubMed
    Score: 0.004
  6. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020 08; 158:104899.
    View in: PubMed
    Score: 0.004
  7. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019 10; 6(10):e655-e666.
    View in: PubMed
    Score: 0.004
  8. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection. J Antimicrob Chemother. 2018 09 01; 73(9):2524-2528.
    View in: PubMed
    Score: 0.003
  9. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
    View in: PubMed
    Score: 0.003
  10. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
    View in: PubMed
    Score: 0.003
  11. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
    View in: PubMed
    Score: 0.003
  12. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 04; 37(4):514-528.
    View in: PubMed
    Score: 0.003
  13. ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Pharmacology. 2015; 96(3-4):163-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.